Anoop P Patel
Overview
Explore the profile of Anoop P Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
7796
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bomsztyk K, Mar D, Denisenko O, Powell S, Vishnoi M, Yin Z, et al.
Lab Invest
. 2024 Oct;
104(12):102160.
PMID: 39426568
Precision oncology is driven by biomarkers. For glioblastoma multiforme (GBM), the most common malignant adult primary brain tumor, O-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation is an important prognostic and treatment...
2.
Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S, et al.
Sci Adv
. 2024 Jun;
10(23):eadj7706.
PMID: 38848360
Poor prognosis and drug resistance in glioblastoma (GBM) can result from cellular heterogeneity and treatment-induced shifts in phenotypic states of tumor cells, including dedifferentiation into glioma stem-like cells (GSCs). This...
3.
OConnor S, Garcia L, Hoover R, Patel A, Bartelle B, Hugnot J, et al.
bioRxiv
. 2024 Apr;
PMID: 38659838
Single-cell transcriptomics has unveiled a vast landscape of cellular heterogeneity in which the cell cycle is a significant component. We trained a high-resolution cell cycle classifier (ccAFv2) using single cell...
4.
Liu M, Ji Z, Jain V, Smith V, Hocke E, Patel A, et al.
Acta Neuropathol Commun
. 2024 Apr;
12(1):64.
PMID: 38650010
Glioblastoma (GBM) remains an untreatable malignant tumor with poor patient outcomes, characterized by palisading necrosis and microvascular proliferation. While single-cell technology made it possible to characterize different lineage of glioma...
5.
Turkarslan S, He Y, Hothi P, Murie C, Nicolas A, Kannan K, et al.
medRxiv
. 2024 Apr;
PMID: 38633778
Grade IV glioma, formerly known as glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor, and its treatment remains challenging in part due to extensive interpatient...
6.
Nuechterlein N, Shelbourn A, Szulzewsky F, Arora S, Casad M, Pattwell S, et al.
Genes Dev
. 2024 Apr;
38(5-6):273-288.
PMID: 38589034
Glioblastoma is universally fatal and characterized by frequent chromosomal copy number alterations harboring oncogenes and tumor suppressors. In this study, we analyzed exome-wide human glioblastoma copy number data and found...
7.
Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S, et al.
bioRxiv
. 2024 Feb;
PMID: 38370784
Poor prognosis and drug resistance in glioblastoma (GBM) can result from cellular heterogeneity and treatment-induced shifts in phenotypic states of tumor cells, including dedifferentiation into glioma stem-like cells (GSCs). This...
8.
Hardigan A, Jackson J, Patel A
Semin Neurol
. 2023 Nov;
43(6):810-824.
PMID: 37963582
The care of patients with both high-grade glioma and low-grade glioma necessitates an interdisciplinary collaboration between neurosurgeons, neuro-oncologists, neurologists and other practitioners. In this review, we aim to detail the...
9.
Lerner E, Woroniecka K, DAnniballe V, Wilkinson D, Mohan A, Lorrey S, et al.
Nat Cancer
. 2023 Aug;
4(9):1258-1272.
PMID: 37537301
The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8 T cells recognizing cognate antigens presented in the context of target cell major histocompatibility...
10.
Singh K, Hotchkiss K, Parney I, de Groot J, Sahebjam S, Sanai N, et al.
Nat Med
. 2023 Jul;
29(10):2402-2405.
PMID: 37488293
No abstract available.